arrow
M

Max J. Gordon

national institutes of health
H指数:17
被引数:943

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphoma

一項关于romidepsin、azacitidine、dexamethasone和lenalidomide在复发或难治性T细胞淋巴瘤中的1期临床试验

2026-02-160
OAAI
Global genotype by environment prediction competition reveals that diverse modeling strategies can deliver satisfactory maize yield estimates

通过环境预测竞争的全球基因型表明,不同的建模策略可以提供令人满意的玉米产量估计

2024-11-221
OA
A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

一项关于达鲁珠单抗、卡非佐米和地塞米松(DKd)在高危冒烟型多发性骨髓瘤患者中的2期适应性研究

BLOOD
IF23.1
2024-11-050
PRE
Phase lb/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naive Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease

维奈克拉、依鲁替尼、泼尼松、奥滨尤妥珠单抗和来那度胺(ViPOR)在复发/难治性及初治套细胞淋巴瘤中的lb/2期研究:安全性、有效性和微小残留病初步分析

BLOOD
IF23.1
2024-11-050
PRE
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study
CANCER
IF5.1
2023-11-204
PRE
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
2023-07-1322
OAAI
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
2023-05-245
OAAI
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
2021-12-0728
OAAI
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era
2021-08-1015
OAAI